Mirxes Holding Company Limited, a Singapore-based biotech firm, announced July 25 that it has filed a listing application with The Stock Exchange of Hong Kong Limited following the receipt of $50 million in Series D funding.
According to Mirxes, the Series D funding is anchored by existing and new investors, including Beijing Fupu, in which the Management Committee of Zhejiang Anji Economic Development Zone has an indirect majority stake.
EDB Investments Pte Ltd, wholly owned by the Singapore Economic Development Board, Agency for Science, Technology and Research, Singapore's lead public sector R&D agency for scientific discovery and technological innovation, Mitsui & Co., Ltd., a company listed on various Japanese stock exchanges, and NHH Venture Fund also took part in the round.
The funding, according to the statement, will be critical in accelerating Mirxes' delivery of cutting-edge cancer early detection blood tests and preventive healthcare solutions in major markets.
The new funding will primarily be used to increase the adoption and penetration of Mirxes' flagship stomach cancer blood test, GASTROClearTM, in major Asia-Pacific markets such as Southeast Asia, China, and Japan.
It will also be used to accelerate the development and commercialization of Mirxes' maturing clinical pipeline, which includes a blood-based colorectal cancer screening test and a multi-cancer early detection test under Project CADENCE, an ambitious project to develop a single blood test for the early detection of nine high-mortality cancers using the company's first-in-class RNA technology and other complementary biomarker technologies.
.jpg "Technology in Cancer Care: A story of evolving paradigms")
.jpg "Bringing Shop Floor to Manufacturer's palm: Smart Factory Solutions for tomorrow")
